NCT05094180

Brief Summary

Randomized-controlled trial to assess the safety of remote consultations (both video and teleconsultation) in the follow-up of patients in the hospital setting. A total of 2136 patients will be randomly allocated into one of the three study arms: A) face-to-face consultation (control) B) Remote consultation (telephone or video consultation). Primary outcome will be the frequency of complications of the underlying disease, including adverse reactions to the treatment of the underlying disease. To be eligible for remote consultation, patients have to have adequate digital literacy at physician discretion, technological capacity to use the video conferencing software, and undergo a type of follow-up that, due to the moderate complexity of the pathology, do not require physical examinations. Patients followed up in more than three departments, those with visual or hearing impairments that may hamper patient-physician communication, and those enrolled in another clinical trial that requires an experimental intervention during the follow-up will be excluded from the study. Physicians can schedule and cancel appointments at their discretion. At least three visits should be scheduled in the study setting: the baseline visit (i.e., screening visit), intermediate visits (pre-defined by the physician based on the follow-up needed for managing the baseline condition), and the final visit (i.e., either the follow-up visit closest to 12 ± 2 months after enrollment or before in case of discharge or early discontinuation). The primary objective will be assessed using a non-inferiority analysis of the cumulative incidence of complications of the baseline disease between remote consultation (video and teleconsultation arms) and face-to-face consultation, using a non-inferiority margin of 2%. The analysis will be based on a modified binomial test to assess the non-inferiority of an experimental intervention vs. a control group in a three-arm trial. The primary analysis will be conducted on a per-protocol study sample, which will include all participants who have finished the study and have not been withdrawn because of non-allowed visits using modalities other than scheduled.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
2,136

participants targeted

Target at P75+ for not_applicable

Timeline
8mo left

Started Dec 2021

Longer than P75 for not_applicable

Geographic Reach
1 country

3 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress87%
Dec 2021Dec 2026

First Submitted

Initial submission to the registry

October 3, 2021

Completed
23 days until next milestone

First Posted

Study publicly available on registry

October 26, 2021

Completed
1 month until next milestone

Study Start

First participant enrolled

December 1, 2021

Completed
4.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 31, 2026

Expected
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2026

Last Updated

June 25, 2025

Status Verified

June 1, 2025

Enrollment Period

4.7 years

First QC Date

October 3, 2021

Last Update Submit

June 23, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Complications of the underlying disease

    Frequency of complications of the underlying disease, including adverse reactions to the treatment of the underlying disease

    12 months

Secondary Outcomes (8)

  • Severe complications of the baseline disease

    12 months

  • Treatment Serious Adverse Event

    12 months

  • Avoidable hospitalizations

    12 months

  • Number of unscheduled medical contacts

    12 months

  • Care process indicators

    12 months

  • +3 more secondary outcomes

Study Arms (2)

Face-to-face consultation

OTHER
Other: Face-to-face appointment

Remote consultation (telephone or video consultation mode)

ACTIVE COMPARATOR
Other: Remote consultation (telephone or video consultation mode)

Interventions

Participants will be scheduled with face-to-face appointments as usual (control arm). All phone calls (except reminders for scheduled visits) performed by the physician during the study will be recorded. Per protocol, participants allocated in the control arm can receive up to 25% of physician-doctor interactions by phone (that is, one phone call allowed for three face-to-face appointments).

Face-to-face consultation

Patients will be seen through one of the two remote consultation modalities: video consultation or telephone. Patients will receive a reminder by text or call before the appointment. In the case of telephone consultation, patients will be informed of the date and time slot in which they must wait for the doctor's call. At the time of the appointment, the doctor will call the contact phone number of the patients and/or their family members, starting with the first contact number that appears in the patient's medical history, and using the rest of the contacts available if there is no response. . In the case of video consultation, at the time of the appointment, patients will receive a link to the application that manages the teleconsultation. Once in the application, they will remain in the virtual waiting room until the doctor switches to the videoconference.

Remote consultation (telephone or video consultation mode)

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Men and women of any age.
  • Possibility of making consultations by telephone, at the discretion of the investigator, taking into account the severity and complexity of the baseline pathology and the objective of health care.
  • Forecast to carry out follow-up in external consultation.
  • Agreement to be attended through a non-face-to-face system.
  • Ability to connect to the video consultation system.
  • Device compatible with the video consultation system.
  • Possibility of collaborating in the necessary evaluations.
  • Legal capacity to give informed consent.

You may not qualify if:

  • Need to carry out physical examinations, visualize the patient in person or perform techniques that involve face-to-face visits.
  • Need for face-to-face consultation due patient's clinical situation.
  • Follow-up by more than three medical specialists.
  • Visual, hearing or functional impairments that may hamper patient-physician communication.
  • Patients enrolled in another clinical trial that requires an experimental intervention during the follow-up.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Hospital Residència Sant Camil

Sant Pere de Ribes, Barcelona, 08810, Spain

RECRUITING

Hospital Comarcal de l'Alt Penedès

Vilafranca del Penedès, Barcelona, 08720, Spain

RECRUITING

Centre de Rehabilitació

Vilanova i la Geltrú, Barcelona, 08800, Spain

NOT YET RECRUITING

Related Publications (1)

  • Rodriguez-Molinero A, Carot-Sans G, Escrig R, Tebe C, Arce J, Perez-Lopez C, Ballesta S, Verdejo G, Cedeno A, Riera-Pagespetit M, Vivas-Angeles S, Alarcon JL, Navarro I, Toro S, Mateo L, Torres AJ, Delmas G, Camell H, Chamero A, Gasol M, Piera-Jimenez J; ECASeT Research Group. Study protocol of a randomized controlled trial to assess safety of teleconsultation compared with face-to-face consultation: the ECASeT study. Trials. 2023 Dec 8;24(1):797. doi: 10.1186/s13063-023-07679-1.

MeSH Terms

Interventions

Remote Consultation

Intervention Hierarchy (Ancestors)

Referral and ConsultationProfessional PracticeOrganization and AdministrationHealth Services AdministrationTelemedicineDelivery of Health CarePatient Care Management

Central Study Contacts

Alejandro Rodríguez-Molinero, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
OTHER
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 3, 2021

First Posted

October 26, 2021

Study Start

December 1, 2021

Primary Completion (Estimated)

July 31, 2026

Study Completion (Estimated)

December 31, 2026

Last Updated

June 25, 2025

Record last verified: 2025-06

Data Sharing

IPD Sharing
Will not share

Locations